| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.004 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.005 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.005 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |